Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Authors:
- 12 June 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (496)
Abstract
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti–4-1BB antibodies, although effective preclinically, has not advanced to phase 3 trials because they have been hampered by both dependency on Fcγ receptor–mediated hyperclustering and hepatotoxicity. To overcome these issues, we engineered proteins simultaneously targeting 4-1BB and a tumor stroma or tumor antigen: FAP–4-1BBL (RG7826) and CD19–4-1BBL. In the presence of a T cell receptor signal, they provide potent T cell costimulation strictly dependent on tumor antigen–mediated hyperclustering without systemic activation by FcγR binding. We could show targeting of FAP–4-1BBL to FAP-expressing tumor stroma and lymph nodes in a colorectal cancer–bearing rhesus monkey. Combination of FAP–4-1BBL with tumor antigen–targeted T cell bispecific (TCB) molecules in human tumor samples led to increased IFN-γ and granzyme B secretion. Further, combination of FAP– or CD19–4-1BBL with CEA-TCB (RG7802) or CD20-TCB (RG6026), respectively, resulted in tumor remission in mouse models, accompanied by intratumoral accumulation of activated effector CD8+ T cells. FAP– and CD19–4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.Keywords
Funding Information
- Clinical Center (P40 OD012217)
- Clinical Center (P30CA012197-39)
- Swiss National Science Foundation (320030_162575)
- NCAT (UL1TR001420)
This publication has 62 references indexed in Scilit:
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesProceedings of the National Academy of Sciences, 2011
- Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector FunctionJournal of Immunotherapy, 2011
- Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanomaMolecular Oncology, 2011
- 4-1BB signaling beyond T cellsCellular & Molecular Immunology, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Integration, scaling, space-group assignment and post-refinementActa Crystallographica Section D Structural Biology, 2010
- p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivoBlood, 2004
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D Structural Biology, 1994